LEVI A GARRAWAY, M.D.
Osteopathic Medicine in Boston, MA

2013005, Mar 7, 2013

Mar 9, 2011

13/583056

Levi A. Garraway - Newton MA, US
Cory M. Johannessen - Roslindale MA, US

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

A61K 31/437, C40B 30/04, G01N 33/574, C40B 30/06, A61K 31/4439, A61P 35/00, A61K 31/444, A61K 31/167, A61K 31/166, A61K 31/353, A61K 31/5377, A61K 31/18, C12Q 1/68, A61K 31/44

5142352, 435 611, 506 9, 435 792, 435 74, 506 10, 514338, 514346, 514341, 514300, 514619, 514394, 514456, 5142362, 514605

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.

2013017, Jul 4, 2013

Jul 25, 2012

13/557988

Le Cong - Brookline MA, US
Ann Marie Egloff - Pittsburgh PA, US
Levi A. Garraway - Newton MA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Eric S. Lander - Cambridge MA, US
Nicholas Stransky - Boston MA, US
Aaron D. Tward - Boston MA, US
Feng Zhang - Cambridge MA, US

A61K 38/16, A61K 45/06, A61K 38/46

424 946, 514 193, 435375

The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.

2013014, Jun 6, 2013

Jun 9, 2011

13/701889

Levi A. Garraway - Newton MA, US
Caroline Emery - Brighton MA, US
Nikhil Wagle - Brookline MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA

A61K 31/4745, C07H 21/04, C12N 9/12, C12Q 1/68

514300, 536 232, 4353201, 4352523, 435194, 435 612, 43525233, 435366, 514394

Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.

2012001, Jan 19, 2012

Dec 10, 2009

13/139060

Levi A. Garraway - Newton MA, US
Caroline Emery - Brookline MA, US
Carlos Garcia Echeverria - Basel, CH

Novartis AG - Basel
Dana-Farber Cancer Institute, Inc. - Boston MA

A61K 31/437, C12N 15/63, C12N 9/12, A61P 35/02, C12N 1/21, C12N 5/10, A61P 35/00, C12N 15/54, C12Q 1/68

514300, 536 232, 4353201, 435194, 435 612, 4352523, 43525233, 435325, 435369

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.

8637246, Jan 28, 2014

Feb 22, 2011

13/580651

Levi Garraway - Newton MA, US
Caroline Emery - Brookline MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA

C12Q 1/00, A61P 35/00

435 611, 514 193

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.

2009000, Jan 1, 2009

Jun 8, 2007

11/811149

Mark A. Rubin - Cambridge MA, US
Francesca Demichelis - Cambridge MA, US
Levi A. Garraway - Newton MA, US
William R. Sellers - Brookline MA, US

C12Q 1/68

435 6

Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.